Lantern Pharma(LTRN) - 2024 Q4 - Annual Results

Exhibit 99.1 Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results www.lanternpharma.com Q4 & Year End 2024 Company Updates & Earnings Press Release. pp. 1 ● HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never- smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, position ...